Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00168857
Registration number
NCT00168857
Ethics application status
Date submitted
9/09/2005
Date registered
15/09/2005
Date last updated
8/12/2023
Titles & IDs
Public title
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
Query!
Scientific title
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
Query!
Secondary ID [1]
0
0
502.397
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypertension
0
0
Query!
Diabetic Nephropathies
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - telmisartan
Treatment: Drugs - losartan
Treatment: Drugs: telmisartan
Treatment: Drugs: losartan
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from baseline after one year of treatment in proteinuria (ratio of protein to creatinine as measure in spot urine sample).
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 1 year
Query!
Secondary outcome [1]
0
0
Change from baseline after one year of treatment in the following: glomerular filtration rate; serum creatinine; macroalbuminuria; sodium excretion; high sensitive C-reactive protein; serum aldosterone; and other renal and cardiovascular measures.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 1 year
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Ability to provide written informed consent in accordance with Good Clinical Practice
(GCP) and local legislation
- Age 21-80 years
- Clinical history of type 2 diabetes mellitus, as defined by either:
- Hyperglycaemia not requiring insulin (diet, oral hypoglycaemic agents and
metformin if patients serum creatinine levels were within normal limits.)
- Hyperglycaemia requiring insulin with: no history of diabetic ketoacidosis AND
with either the period between diagnosis and insulin usage >1 year or elevated
fasting or stimulated C-peptide level
- Glycosylated haemoglobin A1 (HbA1c) =10%
- Diabetic nephropathy, as defined by:
- serum creatinine at Screening (Visit 1) =265 µmol/L (3.0 mg/dL) in women and =283
µmol/L (3.2 mg/dL) in men
- urinary protein/creatinine ratio =700 mg/g (measured in spot urine) during the
run-in phase (Visit 2 or Visit 5 retest)
- Hypertension at screening, as defined by either:
- Mean systolic blood pressure (SBP) >130 mmHg and/or mean diastolic blood pressure
(DBP) >80 mmHg in untreated patients
- Patients currently receiving antihypertensive medication (i.e. medications
specifically prescribed to treat hypertension)
- Ability to stop current antihypertensive therapy with Angiotensin Converting Enzyme
Inhibitor (ACE-Is), Angiotensin Receptor Blockers (ARBs) and direct vasodilators, and
to stop chronic immunosuppressive therapy and current therapy with metformin without
risk to the patient (Investigator's discretion).
- All female patients had to have negative results from the urine pregnancy test (UPT)
at Visits 1 and 6 in order to be able to continue in the study.
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Pre-menopausal women (last menstruation =1 year prior to signing informed consent)
who:
- were not surgically sterile or
- were nursing or pregnant or
- were of child-bearing potential and were not practicing acceptable methods of
birth control, or did not plan to continue practicing an acceptable method
throughout the study (Note: Acceptable methods of birth control included
transdermal patch, intra-uterine device, oral, implantable or injectable
contraceptives) AND did not agree to periodic urine pregnancy testing (UPT)
during participation in the study. No exceptions were made.
- Type 1 diabetes mellitus
- Increase of serum creatinine >35% between Visit 1 (Screening) and Visit 5. If
creatinine was increased >35% at Visit 5, the measurement was to be repeated within
five calendar days and if the increase was confirmed, the patient had to be excluded
from the trial for safety reasons.
- Non-diabetic renal disease
- Congestive heart failure (New York Heart Association functional class III or IV)
- Unstable angina, myocardial infarction, coronary artery bypass graft surgery, or
percutaneous coronary intervention within the last three months prior to signing the
informed consent form
- Stroke or transient ischaemic attack within the last six months prior to signing the
informed consent form
- Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
aortic or mitral valve
- Further exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/07/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
860
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Boehringer Ingelheim Investigational Site - Kippa-Ring
Query!
Recruitment hospital [2]
0
0
Lyell McEwin Hospital Department of medicine - Elizabeth
Query!
Recruitment hospital [3]
0
0
Geelong Clinical Research Centre - Geelong
Query!
Recruitment hospital [4]
0
0
Boehringer Ingelheim Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Kippa-Ring
Query!
Recruitment postcode(s) [2]
0
0
- Elizabeth
Query!
Recruitment postcode(s) [3]
0
0
- Geelong
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Vermont
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Wisconsin
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Buenos aIRES
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Coronel Suarez
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Córdoba
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Paraná
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Provincia De Buenos Aires
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Rosario, Santa Fé
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Salta
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Santa Fe
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Belém
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Botucatu
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Juiz De Fora ¿ MG
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Vila Clementino, São Paulo
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Alberta
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
British Columbia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Manitoba
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Nova Scotia
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Ontario
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Quebec
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Saskatchewan
Query!
Country [43]
0
0
Korea, Republic of
Query!
State/province [43]
0
0
Daegu
Query!
Country [44]
0
0
Korea, Republic of
Query!
State/province [44]
0
0
Gyunggido
Query!
Country [45]
0
0
Korea, Republic of
Query!
State/province [45]
0
0
Seoul
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Acapulco Guerrero
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
Col. Sección XVI, Deleg. Tlalpan
Query!
Country [48]
0
0
Mexico
Query!
State/province [48]
0
0
Guadalajara, Jalisco
Query!
Country [49]
0
0
Mexico
Query!
State/province [49]
0
0
Guadalajara
Query!
Country [50]
0
0
Mexico
Query!
State/province [50]
0
0
Metepec
Query!
Country [51]
0
0
Mexico
Query!
State/province [51]
0
0
México, D.F.
Query!
Country [52]
0
0
New Zealand
Query!
State/province [52]
0
0
Auckland
Query!
Country [53]
0
0
New Zealand
Query!
State/province [53]
0
0
Christchurch
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Chiayi
Query!
Country [55]
0
0
Taiwan
Query!
State/province [55]
0
0
Hualien
Query!
Country [56]
0
0
Taiwan
Query!
State/province [56]
0
0
Tainan
Query!
Country [57]
0
0
Taiwan
Query!
State/province [57]
0
0
Taipei
Query!
Country [58]
0
0
Thailand
Query!
State/province [58]
0
0
Bangkok
Query!
Country [59]
0
0
Thailand
Query!
State/province [59]
0
0
Chiang Mai
Query!
Country [60]
0
0
Thailand
Query!
State/province [60]
0
0
Khon Kaen
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers
(ARB) have been shown to slow the decline in kidney function of patients with type 2
diabetes, high blood pressure, and kidney disease. Losartan (COZAAR), is one such drug. The
purpose of this research study is to determine if after one year of treatment telmisartan
(MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN) 80 mg,
another blood pressure lowering drug from the ARB class, is as effective as losartan (COZAAR)
100 mg in reducing the level of urinary protein (indicative of improved kidney function).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00168857
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim Study Coordinator
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00168857
Download to PDF